No acute effects of exogenous glucose-dependent insulinotropic polypeptide on energy intake, appetite, or energy expenditure when added to treatment with a long …
NC Bergmann, LS Gasbjerg, SM Heimbürger… - Diabetes …, 2020 - Am Diabetes Assoc
Diabetes Care, 2020•Am Diabetes Assoc
OBJECTIVE Dual incretin receptor agonists in clinical development have shown reductions
in body weight and hemoglobin A1c (HbA1c) in patients with type 2 diabetes, but the impact
of glucose-dependent insulinotropic polypeptide (GIP) receptor activation remains unclear.
Here, we evaluated the effects of high-dose exogenous GIP on energy intake, energy
expenditure, plasma glucose, and glucose-regulating hormones in patients with type 2
diabetes treated with a long-acting glucagon-like peptide 1 receptor (GLP-1R) agonist …
in body weight and hemoglobin A1c (HbA1c) in patients with type 2 diabetes, but the impact
of glucose-dependent insulinotropic polypeptide (GIP) receptor activation remains unclear.
Here, we evaluated the effects of high-dose exogenous GIP on energy intake, energy
expenditure, plasma glucose, and glucose-regulating hormones in patients with type 2
diabetes treated with a long-acting glucagon-like peptide 1 receptor (GLP-1R) agonist …
OBJECTIVE
Dual incretin receptor agonists in clinical development have shown reductions in body weight and hemoglobin A1c (HbA1c) in patients with type 2 diabetes, but the impact of glucose-dependent insulinotropic polypeptide (GIP) receptor activation remains unclear. Here, we evaluated the effects of high-dose exogenous GIP on energy intake, energy expenditure, plasma glucose, and glucose-regulating hormones in patients with type 2 diabetes treated with a long-acting glucagon-like peptide 1 receptor (GLP-1R) agonist.
RESEARCH DESIGN AND METHODS
In a randomized, double-blind design, men with type 2 diabetes (n = 22, mean ± SEM HbA1c 6.8 ± 0.1% [51 ± 1.5 mmol/mol]) treated with metformin and long-acting GLP-1R agonists were subjected to two 5-h continuous infusions (separated by a washout period of ≥3 days): one with GIP (6 pmol/kg/min) and another with saline (placebo). After 60 min of infusion, a liquid mixed-meal test was performed, and after 270 min of infusion, an ad libitum meal was served for evaluation of energy intake (primary end point).
RESULTS
Energy intake was similar during GIP and placebo infusion (648 ± 74 kcal vs. 594 ± 55 kcal, respectively; P = 0.480), as were appetite measures and energy expenditure. Plasma glucagon and glucose were higher during GIP infusion compared with placebo infusion (P = 0.026 and P = 0.017) as assessed by area under the curve.
CONCLUSIONS
In patients with type 2 diabetes, GIP infusion on top of treatment with metformin and a long-acting GLP-1R agonist did not affect energy intake, appetite, or energy expenditure but increased plasma glucose compared with placebo. These results indicate no acute beneficial effects of combining GIP and GLP-1.
Am Diabetes Assoc
